{"id":"atazanavir-ritonavir-famotidine","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Hyperbilirubinemia (unconjugated)"},{"rate":"5-10","effect":"Jaundice"},{"rate":"10-15","effect":"Nausea"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Rash"},{"rate":"1-2","effect":"Nephrolithiasis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atazanavir is an HIV protease inhibitor that blocks the viral protease enzyme, preventing the maturation of HIV particles and reducing viral load. Ritonavir is a pharmacokinetic booster that inhibits cytochrome P450 metabolism, significantly increasing atazanavir plasma concentrations and allowing for lower, more convenient dosing. Famotidine, an H2-receptor antagonist, reduces gastric acid production to optimize the pH-dependent absorption of atazanavir in the gastrointestinal tract.","oneSentence":"Atazanavir inhibits HIV protease to prevent viral replication, while ritonavir boosts atazanavir levels, and famotidine reduces gastric acid to improve atazanavir absorption.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:43.975Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced adults"}]},"trialDetails":[{"nctId":"NCT01232127","phase":"PHASE4","title":"Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-02","conditions":"HIV","enrollment":25},{"nctId":"NCT00365339","phase":"PHASE1","title":"Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-04","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00384904","phase":"PHASE4","title":"Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-12","conditions":"HIV Infections","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Reyataz"],"phase":"marketed","status":"active","brandName":"Atazanavir/Ritonavir + Famotidine","genericName":"Atazanavir/Ritonavir + Famotidine","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atazanavir inhibits HIV protease to prevent viral replication, while ritonavir boosts atazanavir levels, and famotidine reduces gastric acid to improve atazanavir absorption. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}